Two numbers, one operation
A total knee replacement can be quoted at roughly $9,000 to a self-paying patient at a Chinese hospital. The same procedure can appear on a US hospital bill at close to $95,000. Both figures are real. Neither means quite what it appears to mean.
Price is not a measure of surgical quality. What follows is about money and paperwork: where the gap comes from, which parts survive contact with an invoice, and what changes when you pay out of pocket and hope to reclaim the cost later. It is not medical advice.
What the two numbers actually represent
The $95,000 is normally a billed charge. US hospitals publish a list price for every procedure and item, and that price is the opening position in a negotiation rather than the sum most payers hand over. The $9,000 is normally a self-pay package price at a Chinese international department: one figure covering surgeon, anaesthesia, implant, ward and routine follow-up, quoted to someone paying cash.
So the comparison sets a number almost nobody pays against one that somebody has been asked to pay. The gap does not vanish — even after insurer discounts, what an American payer transfers is usually several times what a self-paying patient pays in China — but how many times depends on which US figure you use. The $9,000 is also not what a local patient with basic medical insurance pays; it is the price of Chinese healthcare sold to an international patient.
What actually drives the price gap
Four things do most of the work, and only one is the implant.
Surgeon and anaesthesia fees
In the US, the surgeon's fee is billed separately from the hospital's facility charge, and so is the anaesthetist's; both are large by international standards. In China, fees for major surgery and anaesthesia are administratively set and low — a systems difference, not a comment on training. Volume is high, while the fee attached to each operation stays modest.
The implant and its list price
In the US the prosthesis is a separate supply line, priced in confidential negotiations between each hospital and each manufacturer: there is no national price and no public price. China brought hip and knee implants into national volume-based procurement in 2021. The National Healthcare Security Administration reports that the May 2024 follow-up round drew demand for around 580,000 implants from over 6,000 hospitals, with selected prices falling by roughly a further 6%. A 2019 State Council plan required public hospitals to cancel the mark-up on consumables. Those policies compress what is often the largest line on the bill.
Ward days and the cost of a bed
Length of stay differs, but not enough to explain the gap. A US knee replacement is often discharged within one to three days, sometimes as a day case; Chinese practice commonly keeps patients longer. The decisive difference is the nightly charge. A US bed carries round-the-clock nursing, pharmacy, sterilisation and hospital overhead, billed accordingly, while ward charges in Chinese public hospitals are capped and low. Fewer nights at a high nightly rate still costs more than more nights at a low one.
Single-payer negotiating power
China's basic medical insurance schemes cover the great majority of the population — official statements put coverage at around 95% — and that volume is used directly as leverage. Centralised procurement sets one national price by inviting manufacturers to compete for guaranteed volume: the buyer is effectively one organisation. Medicare works differently, paying a single bundled case rate for a knee replacement and absorbing the implant cost inside it, but running no national tenders for prostheses. Commercial insurers negotiate individually and confidentially. The result is many prices for one operation, and the weakest position belongs to the buyer with no leverage at all: the uninsured patient paying cash.
The same knee, itemised in two countries
The table is indicative, assembled from published ranges and typical self-pay quotations rather than one hospital's invoice. Read it as the structure of a bill, not a quotation for you.
| Cost line | China, self-paying (indicative) | US, amount billed (indicative) | How the US line is settled |
|---|---|---|---|
| Pre-operative assessment, X-ray, MRI | $200–700 | $1,500–6,000 | Bundled or negotiated |
| Surgeon's fee | $1,000–2,500 | $6,000–15,000 | Separate professional fee |
| Anaesthesia | $300–800 | $1,500–5,000 | Separate professional fee |
| Knee prosthesis | $700–2,500 after national procurement | $15,000–45,000 | Confidential price, inside the case rate |
| Operating theatre and disposables | $700–1,500 | $8,000–20,000 | Facility charge |
| Inpatient ward, whole stay | $150–500, about four nights | $4,000–12,000, one to three nights | High nightly facility rate |
| Physiotherapy and rehabilitation | $200–700 | $1,000–5,000 | Partly separate, billed per visit |
| Labs, imaging and routine follow-up | $200–600 | $1,500–6,000 | Separate claims per test |
| Indicative total | $6,000–12,000; packages often quoted near $9,000 | $40,000–95,000 or more | A negotiated fraction, never the billed figure |
Why US list price is not what an insurer pays
US hospitals must publish their standard charges, and those figures run consistently several times higher than anything an insurer transfers. A 2015 study in the journal Health Affairs found charge-to-cost ratios above ten to one at the most extreme hospitals. The space between list and payment is where discounts, contractual allowances and bad debt are managed.
A bill is not a receipt, and a list price is not a payment.
For an insured patient the number that matters is the negotiated rate, and it is confidential. Medicare's version is fixed by formula and paid as one bundled sum per case. Without insurance, or if your policy will not cover planned surgery abroad, the price you are asked for in the US is often far closer to list. Some hospitals publish self-pay discounts, and it is worth requesting a cash price in writing — but the asymmetry is real: same operation, same hospital, two patients, very different amounts, decided mainly by who is paying.
What is genuinely not cheaper in China
- Imported biologics. Many are priced per vial at levels broadly comparable with Western markets. National price negotiations have cut the cost of several, but a foreign self-paying patient is usually quoted outside the reimbursement system, so any saving may be small.
- Some targeted cancer drugs. Medicines on China's negotiated reimbursement list have fallen sharply in price. Medicines not on it, or not yet approved in China, can cost as much as anywhere — and a drug approved in Europe or the US may not be available at all.
- Private rooms and VIP wards. A private suite in an international department can cost as much per night as a mid-tier Western private hospital.
- What you carry home. Flights and accommodation for a companion, unpaid leave, translation and notarisation, and follow-up with a surgeon who did not operate. If something goes wrong, investigating it at home can mean paying twice.
The cash-flow problem: pay first, claim later
Chinese hospitals generally expect self-paying international patients to pay a deposit at admission and settle the balance before discharge. Your insurer at home normally reimburses afterwards, so the money leaves your account weeks or months before any of it returns.
Three structural facts sharpen this. US Medicare generally does not pay for health care received outside the United States, with only narrow exceptions. Most private international plans cover planned treatment abroad only where it is a named benefit and pre-authorisation is agreed in advance. And travel insurance covers emergencies, not a scheduled operation. In practice you may carry the full amount for four to twelve weeks in a foreign currency while a claim is assessed, and exchange-rate movement between payment and reimbursement can exceed the discount you travelled for. Coordination service fees, where a company is involved, sit outside the hospital bill and should be quoted separately in writing.
Documents to keep for a claim
Claims fail on paperwork more often than on clinical grounds. Ask your insurer in advance which documents and translations it requires, then collect all of this before you leave.
- Pre-authorisation approval letter with its reference number, and any guarantee of payment.
- The itemised official tax invoice with the hospital's seal, listing each item and price separately, in the patient's name exactly as in the passport.
- Proof of payment for every instalment: deposit receipt, card slips, bank transfer confirmations.
- Discharge summary and full medical record, including the operative note and anaesthesia record.
- Implant documentation: brand, model, size, lot or serial numbers and the manufacturer's barcode labels — easy to lose, hard to replace.
- Laboratory, pathology and imaging reports, a disc of the images if available, and pharmacy receipts for medicines bought separately.
- Certified translations of everything above where required, with the translator's certification.
- One indexed folder with scans in the cloud, and paper copies in hand luggage rather than checked in.
What this article is, and what it is not
This is cost and payment information. It is not medical advice and not a treatment recommendation, and it cannot tell you whether a knee replacement is right for you, which implant suits your anatomy, or where the operation should take place. Those are clinical judgements resting on your examination, imaging and general health, and they belong to you and your treating doctor. Outcomes depend far more on case selection, the surgeon's experience, the implant and your rehabilitation than on the price on the invoice.
Every figure here is an indicative range from public sources, and prices and rules change. Ask the hospital for a written, itemised estimate. Ask your insurer what it will pay, and on what evidence.
References
- Centers for Medicare & Medicaid Services — Medicare payment systems, fee schedules and hospital price transparency
- Medicare (US) — Travel outside the U.S.
- The State Council of the People's Republic of China — Reform plan for high-value medical consumables: cancelling the mark-up and zero-margin sale (Chinese, 2019)
- National Healthcare Security Administration, via the State Council portal — Artificial joint procurement, follow-up round (Chinese, May 2024)
- National Healthcare Security Administration of the People's Republic of China — insurance policy, drug and consumable procurement notices (Chinese)
- World Health Organization — Global Health Expenditure Database
- OECD — Health at a Glance: hospital activity, prices and health spending indicators
- Bai G. and Anderson G.F. — Extreme Markup: The Fifty US Hospitals With The Highest Charge-To-Cost Ratios, Health Affairs, 2015